Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 1.00 |
| ▸ | SRC | P12931 | 5/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 3/20 | 1.00 |
| ▸ | PRKCG | P05129 | 3/20 | 1.00 |
| ▸ | PRKCB | P05771 | 3/20 | 1.00 |
| ▸ | PRKCA | P17252 | 3/20 | 1.00 |
| ▸ | PRKCH | P24723 | 3/20 | 1.00 |
| ▸ | PRKCI | P41743 | 3/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 3/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 3/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 3/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 3/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | RGS12 | O14924 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8834907 | 0.90 | EGFR (0.87) | EGFRSRCPRKD3PRKCGPRKCB | |
| SCHEMBL8834140 | 0.89 | EGFR (0.80) | EGFRSRCPRKD3PRKCGPRKCB | |
| SCHEMBL8834940 | 0.88 | EGFR (0.77) | EGFRSRCPRKD3PRKCGPRKCB | |
| SCHEMBL8834462 | 0.87 | EGFR (0.76) | EGFRSRCPRKD3PRKCGPRKCB | |
| SCHEMBL8835011 | 0.86 | EGFR (0.75) | EGFRSRCPRKD3PRKCGPRKCB | |
| SCHEMBL8835167 | 0.86 | EGFR (0.73) | EGFRSRCPRKD3PRKCGPRKCB | |
| SCHEMBL8833729 | 0.86 | EGFR (1.00) | EGFRSRCPRKD3PRKCGPRKCB | |
| SCHEMBL8834476 | 0.83 | EGFR (0.69) | EGFRSRCPRKD3PRKCGPRKCB | |
| SCHEMBL8834026 | 0.83 | BRAF (0.72) | EGFRSRCPRKD3PRKCGPRKCB | |
| SCHEMBL8834258 | 0.82 | EGFR (0.73) | EGFRSRCPRKD3PRKCGPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 357 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107237-A1 | RAS AND EGFR INHIBITORS COMBINATION THERAPY | ERASCA, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20220347108-A1 | PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCE | BAYER AKTIENGESELLSCHAFT (DE) | 2022-11-03 | — | — | US | claimed |
| EP-4041201-A1 | PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCE | Bayer Aktiengesellschaft (DE) | 2022-08-17 | — | — | EP | claimed |
| CN-114514019-A | Method for producing pharmaceutical preparations containing crystalline and amorphous fractions of active substances | 拜耳股份有限公司 | 2022-05-17 | — | — | CN | claimed |
| WO-2021069349-A1 | PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCE | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-15 | — | — | WO | claimed |
| EP-3804701-A1 | METHOD FOR PREPARING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS PORTIONS OF AN ACTIVE SUBSTANCE | Bayer AG (DE) | 2021-04-14 | — | — | EP | claimed |
| EP-3804702-A1 | METHOD FOR PREPARING A PHARMACEUTICAL FORMULATION COMPRISING ACTIVE AGENT, POLYMER AND SURFACTANT | Bayer AG (DE) | 2021-04-14 | — | — | EP | claimed |
| WO-2016127255-A1 | MEDIATION OF INFLAMMATORY RESPONSE USING INHIBITORS OF NETOSIS | NADESALINGAM PALANIYAR (CA) | 2016-08-18 | — | — | WO | claimed |
| US-20100166833-A1 | Compositions, articles and methods for preventing or reducing tobacco-associated damage | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2010-07-01 | — | — | US | claimed |
| US-20090233893-A1 | Methods of Dissolving Beta-Sheet Proteins and Uses Thereof | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2009-09-17 | — | — | US | claimed |
| US-20030060515-A1 | Protein tyrosine kinase inhibitors for treating osteoarthritis | THE OSTEOARTHRITIS SCIENCES, INC. LIQUIDATING TRUST (US) | 2003-03-27 | — | — | US | claimed |
| EP-0850055-A2 | PROTEIN TYROSINE KINASE INHIBITORS FOR TREATING OSTEOARTHRITIS | Osteoarthritis Sciences, Inc. (US) | 1998-07-01 | — | — | EP | claimed |
| WO-1997032589-A1 | COMBINATIONS FOR TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | claimed |
| WO-1997032604-A1 | ANTIPROLIFERATIVE COMBINATIONS, CONTAINING RAF-TARGETED OLIGONUCLEOTIDES AND CHEMOTHERAPEUTIC COMPOUNDS | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | claimed |
| US-5663336-A | IMIDATION OF DIAMINOPHTHALIC ACID TO FORM KINASE INHIBITORS AS ANTITUMOR AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-09-02 | — | — | US | claimed |
| EP-0783887-A2 | Topical compositions for the treatment of hyperproliferative skin disease | CIBA-GEIGY AG (CH) | 1997-07-16 | — | — | EP | claimed |
| WO-1997011692-A2 | PROTEIN TYROSINE KINASE INHIBITORS FOR TREATING OSTEOARTHRITIS | OSTEOARTHRITIS SCIENCES, INC. (US) | 1997-04-03 | — | — | WO | claimed |
| US-5491144-A | KINASE INHIBITORS, ANTITUMOR AGENTS | CIBA-GEIGY CORPORATION (US) | 1996-02-13 | — | — | US | claimed |
| EP-0516588-B1 | Substituted diaminophtalimides and analogues | CIBA GEIGY AG (CH) | 1994-07-13 | — | — | EP | claimed |
| EP-0516588-A1 | Substituted diaminophtalimides and analogues | CIBA-GEIGY AG (CH) | 1992-12-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060515-A1 | Protein tyrosine kinase inhibitors for treating osteoarthritis | MUSK, SRC, GRB2 | EGFR 237/4885SRC 2/4885PRKD3 436/4885 |
| US-20090233893-A1 | Methods of Dissolving Beta-Sheet Proteins and Uses Thereof | CACYBP, HSPBP1, SLC30A7 | EGFR 4457/4885SRC 4508/4885PRKD3 3784/4885 |
| US-20100166833-A1 | Compositions, articles and methods for preventing or reducing tobacco-associated damage | SOD1, SOD3, MGMT | EGFR 3916/4885SRC 4792/4885PRKD3 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.